<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4903">
  <stage>Registered</stage>
  <submitdate>30/03/2015</submitdate>
  <approvaldate>30/03/2015</approvaldate>
  <nctid>NCT02407197</nctid>
  <trial_identification>
    <studytitle>International T1 Multicentre CMR Outcome Study in Patients With Nonischaemic Cardiomyopathies</studytitle>
    <scientifictitle>International T1 Multicentre CMR Study</scientifictitle>
    <utrn />
    <trialacronym>T1-CMR</trialacronym>
    <secondaryid>2011-T1-MC</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiomyopathy</healthcondition>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All cause mortality - all cause mortality</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cardiovascular mortality - composite of sudden cardiac death (SCD), death from HF, death from stroke or thromboembolic event</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Arrhythmic composite endpoint - fatal or aborted SCD (including a documented appropriate shock from ICD)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HF composite end point - HF death and unplanned HF hospitalization</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients fulfilling the criteria of NICM OR

          -  presence of structural heart disease OR

          -  exhibiting myocardial LGE in non-ischemic pattern of LGE on CMR OR

          -  subjects with high pretest probability for cardiomyopathy

          -  persistent symptoms

          -  comorbidities

          -  first degree relative of a patient with known cardiomyopathy

          -  family history of sudden cardiac death (SCD)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  known or suspected myocardial infiltration due to amyloidosis, iron accumulation,
             lipid-storage disease or edema due to active myocardial inflammation

          -  known ischemic heart disease (IHD) based on at least one of the following: significant
             documented coronary artery disease (CAD), previous coronary revascularization,
             previous a history of myocardial infarction, or evidence of ischemic type-LGE or
             significant inducible ischemia on CMR

          -  history of renal disease with a current eGFR&lt;30 mL/min/1.73m2

          -  signifact structural valvular disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational [Patient Registry]</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Vincent's University - Sydney</hospital>
    <postcode>NSW 2010 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>King's College London</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Myocardial fibrosis is the fundamental substrate for the development of heart failure.

      Cardiovascular magnetic resonance (CMR) allows non-invasive assessment of myocardial fibrosis
      based on late gadolinium enhancement (LGE) and T1 mapping.

      Patients: Prospective longitudinal observational multicenter study of consecutive patients
      with suspected or known non-ischemic cardiomyopathy.

      Imaging: Non-invasive measures of myocardial fibrosis: native T1, extracellular volume
      fraction (ECV) and LGE.

      Primary endpoints: all cause and cardiovascular mortality.

      Secondary endpoints: arrhythmic composite and HF composite endpoints.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02407197</trialwebsite>
    <publication>Dabir D, Child N, Kalra A, Rogers T, Gebker R, Jabbour A, Plein S, Yu CY, Otton J, Kidambi A, McDiarmid A, Broadbent D, Higgins DM, Schnackenburg B, Foote L, Cummins C, Nagel E, Puntmann VO. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2014 Oct 21;16:69. doi: 10.1186/s12968-014-0069-x.
Hinojar R, Foote L, Arroyo Ucar E, Jackson T, Jabbour A, Yu CY, McCrohon J, Higgins DM, Carr-White G, Mayr M, Nagel E, Puntmann VO. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. JACC Cardiovasc Imaging. 2015 Jan;8(1):37-46. doi: 10.1016/j.jcmg.2014.07.016. Epub 2014 Dec 10.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eike Nagel, MD, PhD</name>
      <address>King's College London</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Valentina Puentmann, MD, PhD</name>
      <address />
      <phone>+447881943320</phone>
      <fax />
      <email>valentina.puntmann@kgu.de</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>